Trial Search Results

Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer

This phase II/III trial compares the effect of adding chemotherapy before and after surgery versus after surgery alone (usual treatment) in treating patients with stage II-III gallbladder cancer. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before surgery may make the tumor smaller; therefore, may reduce the extent of surgery. Additionally, it may make it easier for the surgeon to distinguish between normal and cancerous tissue. Giving chemotherapy after surgery may kill any remaining tumor cells. This study will determine whether giving chemotherapy before surgery increases the length of time before the cancer may return and whether it will increase a patient's life span compared to the usual approach.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

ECOG-ACRIN Cancer Research Group

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Drug: Cisplatin
  • Drug: Gemcitabine Hydrochloride
  • Procedure: Lymphadenectomy
  • Procedure: Partial Hepatectomy

Phase:

Phase 2/Phase 3

Eligibility


Inclusion Criteria:

   - Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of
   0-1

   - Patient must have histologically-confirmed T2 or T3 gallbladder cancer discovered
   incidentally at the time of or following routine cholecystectomy for presumed benign
   disease

      - NOTE: Patients with histologically-confirmed Tis, T1a, T1b, or T4 tumors are not
      eligible

   - Patient must have undergone initial cholecystectomy within 12 weeks prior to
   randomization

   - Patient must have the ability to understand and the willingness to sign a written
   informed consent document

   - Leukocytes >= 3,000/mcL (obtained =< 28 days prior to randomization)

   - Absolute neutrophil count >= 1,500/mcL (obtained =< 28 days prior to randomization)

   - Platelets >= 100,000/mcL (obtained =< 28 days prior to randomization)

   - Total bilirubin =< institutional upper limit of normal (ULN) except in patients with
   Gilbert's syndrome. Patients with Gilbert's syndrome are eligible if direct bilirubin
   < 1.5 x ULN of the direct bilirubin (obtained =< 28 days prior to randomization)

   - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
   alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x
   institutional ULN (obtained =< 28 days prior to randomization)

   - Serum creatinine =< institutional ULN OR creatinine clearance >= 50 mL/min/1.73 m^2
   (Based on Cockcroft Gault estimation) (obtained =< 28 days prior to randomization)

   - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral
   therapy with undetectable viral load within 6 months of randomization are eligible for
   this trial

   - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral
   load must be undetectable on suppressive therapy, if indicated

   - Patients with a history of hepatitis C virus (HCV) infection must have been treated
   and cured. For patients with HCV infection who are currently on treatment, they are
   eligible if they have an undetectable HCV viral load

   - Patients with a prior or concurrent malignancy whose natural history or treatment does
   not have the potential to interfere with the safety or efficacy assessment of the
   investigational regimen are eligible for this trial

   - Patients with known history or current symptoms of cardiac disease, or history of
   treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac
   function using the New York Heart Association functional classification. To be
   eligible for this trial, patients should be class 2B or better

Exclusion Criteria:

   - Patient must not have any evidence of metastatic disease or inoperable loco-regional
   disease based on high-quality, preoperative, cross-sectional imaging (computed
   tomography [CT] or magnetic resonance imaging [MRI]) of the chest, abdomen, and pelvis
   (C/A/P) obtained within 6 weeks prior to randomization, defined as

      - No radiographic evidence of distant disease (M1 disease)

      - No radiographic evidence of tumor invasion into multiple extrahepatic organs (T4
      disease)

      - No radiographic evidence of distant lymph node involvement (celiac, para-aortic,
      para-caval lymph nodes)

      - No evidence of new-onset ascites

      - Soft tissue thickening within or in direct communication with the gallbladder
      fossa, peri-portal lymph node involvement, involvement of one extrahepatic organ,
      and other disease within the confines of what constitutes 'localized resectable'
      disease are allowable

   - Women must not be pregnant or breast feeding due to the potential harm to unborn fetus
   and possible risk for adverse events in nursing infants with the treatment regimens
   being used. All females of child bearing potential must have a serum or urine
   pregnancy test to rule out pregnancy within 14 days prior to randomization. A female
   of childbearing potential is defined as any woman, regardless of sexual orientation or
   whether they have undergone tubal ligation, who meets the following criteria: 1) has
   achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral
   oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer
   therapy does not rule out childbearing potential) for at least 24 consecutive months
   (i.e., has had menses at any time in the preceding 24 consecutive months)

   - Women of childbearing potential and sexually active males must not expect to conceive
   or father children by being strongly advised to use accepted and effective method(s)
   of contraception or to abstain from sexual intercourse for the duration of their
   participation in the study

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Daniel Holguin
650-736-3379
Recruiting